Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hartmann, P.
Right arrow Articles by Diehl, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartmann, P.
Right arrow Articles by Diehl, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1562-1569, 2003
© 2003 European Society for Medical Oncology

Original Paper

BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection

P. Hartmann1,2,+, U. Rehwald1, B. Salzberger2, C. Franzen2, M. Sieber1, A. Wöhrmann1 and V. Diehl1

1 Department of Internal Medicine I, University of Cologne, Cologne; 2 Department of Internal Medicine I, University of Regensburg, Regensburg, Germany

Received 14 March 2003; accepted 5 June 2003

Background:

Hodgkin’s disease (HD) is the most common non-AIDS-defining tumor diagnosed in HIV-infected patients. Antineoplastic treatment is difficult considering the underlying immunodeficiency caused by HIV itself and may increase the risk of opportunistic infections. The purpose of this study was to evaluate the efficacy and safety of the chemotherapeutic regimen bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) in HIV-infected patients with HD (HIV-HD).

Patients and methods:

Twelve patients with HIV-HD were scheduled to receive six cycles of BEACOPP. Five patients received concomitant antiretroviral therapy. Two patients received additional radiotherapy. Restaging was carried out after three and six cycles of chemotherapy. CD4 counts and HIV RNA levels were regularly monitored during the course of chemotherapy.

Results:

Complete remission (CR) was achieved in all patients. Of 12 patients, eight patients received the intended six cycles of BEACOPP. Two patients died of opportunistic infections within the treatment period, one patient died of a relapse after 26 months. The other nine patients remain in CR for their individual follow-up period, median 49 months (range 13–108). The most commonly observed toxicity was bone marrow suppression with National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 3/4 leukopenia in 75% of all cases. The mean decline of CD4+ lymphocytes was 238 ± 230/µl, with a mean recovery of 272 ± 329/µl 6 months after the last cycle. Plasma levels of HIV RNA increased moderately or even declined under chemotherapy if highly active anti-retroviral therapy was given concomitantly with BEACOPP.

Conclusions:

The BEACOPP regimen is feasible and highly effective in HIV-HD patients. With respect to its overall moderate toxicity, BEACOPP is a safe regimen even in the immunocompromised patient.

Key words: antiretroviral therapy, chemotherapy, HIV infection, Hodgkin’s disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J.-P. Spano, D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler, and D. Khayat
AIDS-Related Malignancies: State of the Art and Therapeutic Challenges
J. Clin. Oncol., October 10, 2008; 26(29): 4834 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. M. Connors
Challenging Problems: Coincident Pregnancy, HIV Infection, and Older Age
Hematology, January 1, 2008; 2008(1): 334 - 339.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. Garcia-Noblejas, S. Nieto, R. Liberal, J. Cannata, J.L. Steegmann, J.M. Fernandez-Ranada, and R. Arranz
Intracerebral hogkin's lymphoma in a patient with human immunodeficiency virus
Haematologica, June 1, 2007; 92(6): e72 - e73.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
B. Xicoy, J.-M. Ribera, P. Miralles, J. Berenguer, R. Rubio, B. Mahillo, M.-E. Valencia, E. Abella, A. Lopez-Guillermo, A. Sureda, et al.
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma
Haematologica, February 1, 2007; 92(2): 191 - 198.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. H. Navarro and L. D. Kaplan
AIDS-related lymphoproliferative disease
Blood, January 1, 2006; 107(1): 13 - 20.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
S. T. Lim and A. M. Levine
Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma
CA Cancer J Clin, July 1, 2005; 55(4): 229 - 241.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. C. Cheung, L. Pantanowitz, and B. J. Dezube
AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy
Oncologist, June 1, 2005; 10(6): 412 - 426.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.